{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:18:19Z","timestamp":1793902699496,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-68112-6","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:49:34Z","timestamp":1767714574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Intrathecal CRISPR-edited allogeneic IL-13R\u03b12 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Xuetao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4539-7454","authenticated-orcid":false,"given":"Xian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-6803","authenticated-orcid":false,"given":"Huabing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoci","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0436-1028","authenticated-orcid":false,"given":"Wenjuan","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xigang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0845","authenticated-orcid":false,"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4049-0214","authenticated-orcid":false,"given":"Yuzhang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5297-6967","authenticated-orcid":false,"given":"Yulun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"68112_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","volume":"20","author":"QT Ostrom","year":"2018","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol. 20, iv1\u2013iv86 (2018).","journal-title":"Neuro Oncol."},{"key":"68112_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","volume":"21","author":"C Horbinski","year":"2023","unstructured":"Horbinski, C. et al. NCCN guidelines(R) insights: central nervous system cancers, Version 2.2022. J. Natl. Compr. Canc Netw. 21, 12\u201320 (2023).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"68112_CR3","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306\u20132316 (2017).","journal-title":"JAMA"},{"key":"68112_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1586\/ern.11.37","volume":"11","author":"T Walbert","year":"2011","unstructured":"Walbert, T. & Mikkelsen, T. Recurrent high-grade glioma: a diagnostic and therapeutic challenge. Expert Rev. Neurother. 11, 509\u2013518 (2011).","journal-title":"Expert Rev. Neurother."},{"key":"68112_CR5","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/neuonc\/noy032","volume":"20","author":"SJ Bagley","year":"2018","unstructured":"Bagley, S. J. et al. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 20, 1429\u20131438 (2018).","journal-title":"Neuro Oncol."},{"key":"68112_CR6","doi-asserted-by":"publisher","first-page":"817296","DOI":"10.3389\/fimmu.2022.817296","volume":"13","author":"YJ Lin","year":"2022","unstructured":"Lin, Y. J., Mashouf, L. A. & Lim, M. CAR T cell therapy in primary brain tumors: current investigations and the future. Front Immunol. 13, 817296 (2022).","journal-title":"Front Immunol."},{"key":"68112_CR7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/2159-8290.CD-17-1368","volume":"8","author":"A Taraseviciute","year":"2018","unstructured":"Taraseviciute, A. et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 8, 750\u2013763 (2018).","journal-title":"Cancer Discov."},{"key":"68112_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","volume":"476","author":"S Xu","year":"2020","unstructured":"Xu, S. et al. Immunotherapy for glioma: current management and future application. Cancer Lett. 476, 1\u201312 (2020).","journal-title":"Cancer Lett."},{"key":"68112_CR9","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med"},{"key":"68112_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","volume":"20","author":"G Lombardi","year":"2019","unstructured":"Lombardi, G. et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 20, 110\u2013119 (2019).","journal-title":"Lancet Oncol."},{"key":"68112_CR11","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp, R. et al. NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48, 2192\u20132202 (2012).","journal-title":"Eur. J. Cancer"},{"key":"68112_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/35869","volume":"391","author":"VM Braud","year":"1998","unstructured":"Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C. Nature 391, 795\u2013799 (1998).","journal-title":"Nature"},{"key":"68112_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"68112_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"68112_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DB Cox","year":"2015","unstructured":"Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med 21, 121\u2013131 (2015).","journal-title":"Nat. Med"},{"key":"68112_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3349\/ymj.2007.48.1.11","volume":"48","author":"SY Choo","year":"2007","unstructured":"Choo, S. Y. The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med J. 48, 11\u201323 (2007).","journal-title":"Yonsei Med J."},{"key":"68112_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu, H. et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24, 566\u2013578 e7 (2019).","journal-title":"Cell Stem Cell"},{"key":"68112_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omtm.2022.05.010","volume":"26","author":"Y Kitano","year":"2022","unstructured":"Kitano, Y. et al. Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application. Mol. Ther. Methods Clin. Dev. 26, 15\u201325 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"68112_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai, H. et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122, 1341\u20131349 (2013).","journal-title":"Blood"},{"key":"68112_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep21757","volume":"6","author":"H Torikai","year":"2016","unstructured":"Torikai, H. et al. Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Sci. Rep. 6, 21757 (2016).","journal-title":"Sci. Rep."},{"key":"68112_CR21","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res"},{"key":"68112_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil, S. et al. Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185\u2013199 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68112_CR23","doi-asserted-by":"publisher","first-page":"680480","DOI":"10.3389\/fimmu.2021.680480","volume":"12","author":"B Duygu","year":"2021","unstructured":"Duygu, B. et al. HLA Class I molecules as immune checkpoints for NK cell alloreactivity and anti-viral immunity in kidney transplantation. Front Immunol. 12, 680480 (2021).","journal-title":"Front Immunol."},{"key":"68112_CR24","first-page":"100638","volume":"33","author":"W Sun","year":"2022","unstructured":"Sun, W. et al. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence. Cancer Treat. Res Commun. 33, 100638 (2022).","journal-title":"Cancer Treat. Res Commun."},{"key":"68112_CR25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/mc.23213","volume":"59","author":"S Meril","year":"2020","unstructured":"Meril, S. et al. Targeting glycosylated antigens on cancer cells using siglec-7\/9-based CAR T-cells. Mol. Carcinog. 59, 713\u2013723 (2020).","journal-title":"Mol. Carcinog."},{"key":"68112_CR26","doi-asserted-by":"publisher","first-page":"110703","DOI":"10.1016\/j.intimp.2023.110703","volume":"123","author":"H Ouyang","year":"2023","unstructured":"Ouyang, H. et al. Baseline and early changes in the neutrophil-lymphocyte ratio (NLR) predict survival outcomes in advanced colorectal cancer patients treated with immunotherapy. Int Immunopharmacol. 123, 110703 (2023).","journal-title":"Int Immunopharmacol."},{"key":"68112_CR27","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1007\/s13346-021-01008-2","volume":"11","author":"Y Rui","year":"2021","unstructured":"Rui, Y. & Green, J. J. Overcoming delivery barriers in immunotherapy for glioblastoma. Drug Deliv. Transl. Res 11, 2302\u20132316 (2021).","journal-title":"Drug Deliv. Transl. Res"},{"key":"68112_CR28","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N. Engl. J. Med 390, 1290\u20131298 (2024).","journal-title":"N. Engl. J. Med"},{"key":"68112_CR29","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med 30, 1320\u20131329 (2024).","journal-title":"Nat. Med"},{"key":"68112_CR30","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown, C. E. et al. Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med 30, 1001\u20131012 (2024).","journal-title":"Nat. Med"},{"key":"68112_CR31","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown, C. E. et al. Bioactivity and safety of IL13Ralpha2-Redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin. Cancer Res 21, 4062\u20134072 (2015).","journal-title":"Clin. Cancer Res"},{"key":"68112_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jocn.2020.01.086","volume":"74","author":"W Haque","year":"2020","unstructured":"Haque, W. et al. Patterns of management and outcomes of unifocal versus multifocal glioblastoma. J. Clin. Neurosci. 74, 155\u2013159 (2020).","journal-title":"J. Clin. Neurosci."},{"key":"68112_CR33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1001\/archneur.1995.00540330094020","volume":"52","author":"MC Chamberlain","year":"1995","unstructured":"Chamberlain, M. C. et al. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch. Neurol. 52, 912\u2013917 (1995).","journal-title":"Arch. Neurol."},{"key":"68112_CR34","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med 29, 2844\u20132853 (2023).","journal-title":"Nat. Med"},{"key":"68112_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi, A. et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360\u2013365 (2022).","journal-title":"Nature"},{"key":"68112_CR36","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke, D. M., et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"68112_CR37","doi-asserted-by":"publisher","first-page":"e1331","DOI":"10.1002\/cti2.1331","volume":"10","author":"MP Brown","year":"2021","unstructured":"Brown, M. P., Ebert, L. M. & Gargett, T. Erratum: clinical chimeric antigen receptor T-cell therapy: a new and promising treatment modality for glioblastoma. Clin. Transl. Immunol. 10, e1331 (2021).","journal-title":"Clin. Transl. Immunol."},{"key":"68112_CR38","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med 6, 224ra225 (2014).","journal-title":"Sci. Transl. Med"},{"key":"68112_CR39","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"68112_CR40","first-page":"723","volume":"11","author":"ES Waxman","year":"2020","unstructured":"Waxman, E. S. & Gerber, D. L. Pseudoprogression and immunotherapy phenomena. J. Adv. Pr. Oncol. 11, 723\u2013731 (2020).","journal-title":"J. Adv. Pr. Oncol."},{"key":"68112_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000065718","volume":"63","author":"AA Brandes","year":"2002","unstructured":"Brandes, A. A. et al. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63, 38\u201341 (2002).","journal-title":"Oncology"},{"key":"68112_CR42","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/cncr.11949","volume":"100","author":"SM Chang","year":"2004","unstructured":"Chang, S. M. et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer 100, 605\u2013611 (2004).","journal-title":"Cancer"},{"key":"68112_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1023\/A:1008382516636","volume":"12","author":"M Brada","year":"2001","unstructured":"Brada, M. et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12, 259\u2013266 (2001).","journal-title":"Ann. Oncol."},{"key":"68112_CR44","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","volume":"83","author":"WK Yung","year":"2000","unstructured":"Yung, W. K. et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588\u2013593 (2000).","journal-title":"Br. J. Cancer"},{"key":"68112_CR45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2165\/11203890-000000000-00000","volume":"70","author":"MD Moen","year":"2010","unstructured":"Moen, M. D. Bevacizumab: in previously treated glioblastoma. Drugs 70, 181\u2013189 (2010).","journal-title":"Drugs"},{"key":"68112_CR46","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/PPO.0000000000000326","volume":"24","author":"MM Kim","year":"2018","unstructured":"Kim, M. M., Umemura, Y. & Leung, D. Bevacizumab and glioblastoma: past, present, and future directions. Cancer J. 24, 180\u2013186 (2018).","journal-title":"Cancer J."},{"key":"68112_CR47","first-page":"e2303215","volume":"10","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Hu, Y. & Mei, H. Advances in CAR-engineered immune cell generation: engineering approaches and sourcing strategies. Adv. Sci. (Weinh.) 10, e2303215 (2023).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"68112_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez, M. & Moon, E. K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 10, 128 (2019).","journal-title":"Front Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68112-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:02:02Z","timestamp":1770339722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-68112-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68112"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-68112-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2983817\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1362"}}